A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID. The study ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene ...
Drugmaker Pfizer is arguing to the state Supreme Court that $8.6 million in punitive damages should not have been awarded in a hormone-replacement therapy case without evidence that its subsidiary ...
Pfizer PFE and partner BioNTech BNTX announced that a phase III study evaluating an mRNA-based combination vaccine candidate against influenza and COVID-19 missed one of its two primary immunogenicity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results